Corton Capital Inc. decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 37.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 869 shares of the medical research company’s stock after selling 523 shares during the quarter. Corton Capital Inc.’s holdings in Amgen were worth $211,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Amgen by 1.4% in the first quarter. Vanguard Group Inc. now owns 47,329,045 shares of the medical research company’s stock worth $11,445,110,000 after buying an additional 668,036 shares during the period. State Street Corp boosted its holdings in Amgen by 1.2% in the 1st quarter. State Street Corp now owns 30,504,420 shares of the medical research company’s stock worth $7,376,579,000 after acquiring an additional 357,413 shares during the period. FMR LLC grew its position in Amgen by 24.9% in the second quarter. FMR LLC now owns 8,911,384 shares of the medical research company’s stock valued at $2,168,140,000 after acquiring an additional 1,774,223 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Amgen by 1.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock worth $2,132,778,000 after purchasing an additional 94,565 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in shares of Amgen by 2.8% during the first quarter. Royal Bank of Canada now owns 4,380,588 shares of the medical research company’s stock worth $1,059,316,000 after purchasing an additional 117,644 shares in the last quarter. 77.14% of the stock is owned by hedge funds and other institutional investors.
Amgen Stock Down 0.1 %
Shares of Amgen stock opened at $285.57 on Friday. The stock has a market capitalization of $152.37 billion, a price-to-earnings ratio of 22.90, a PEG ratio of 2.09 and a beta of 0.65. Amgen Inc. has a twelve month low of $209.00 and a twelve month high of $296.67. The company has a current ratio of 1.68, a quick ratio of 1.35 and a debt-to-equity ratio of 10.17. The business’s 50 day simple moving average is $267.76 and its 200-day simple moving average is $251.80.
Amgen Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Thursday, December 8th. Shareholders of record on Thursday, November 17th were paid a $1.94 dividend. The ex-dividend date was Wednesday, November 16th. This represents a $7.76 annualized dividend and a dividend yield of 2.72%. Amgen’s payout ratio is currently 62.23%.
In related news, SVP Nancy A. Grygiel sold 545 shares of the stock in a transaction that occurred on Tuesday, November 8th. The stock was sold at an average price of $293.54, for a total value of $159,979.30. Following the completion of the transaction, the senior vice president now directly owns 13,009 shares of the company’s stock, valued at approximately $3,818,661.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.46% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on AMGN shares. Robert W. Baird reiterated an “underperform” rating and issued a $185.00 price objective on shares of Amgen in a report on Tuesday, September 13th. Royal Bank of Canada raised their price objective on Amgen from $235.00 to $240.00 and gave the company a “sector perform” rating in a research note on Friday, November 4th. Morgan Stanley upped their target price on Amgen from $279.00 to $282.00 and gave the company an “overweight” rating in a research report on Friday, November 4th. Truist Financial raised their price target on shares of Amgen from $266.00 to $280.00 and gave the stock a “hold” rating in a research report on Tuesday, November 8th. Finally, Piper Sandler upped their price target on shares of Amgen from $278.00 to $297.00 in a report on Monday. Four research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $249.47.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
- Is It Time To Throw In The Towel On Gamestop?
- Why You Should Avoid Carvana Even if it Avoids Bankruptcy
- Are Investors Hearing The End Of Spotify’s Downtrend?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.